Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Hernando

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Cell Reports|August 4, 2023
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotypeEstefania Cuesta-Borràs, Cándida Salvans, Oriol Arqués, et al.
Translational Oncology|April 9, 2023
Impact of the COVID-19 pandemic in the early-onset colorectal cancerIosune Baraibar, Ariadna García, Francesc Salvà, et al.
Nature Communications|August 8, 2024
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine CarcinomasJaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Critical Care (London, England)|September 19, 2008
Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trialGisela Del Carmen De La Rosa, Jorge Hernando Donado, Alvaro Humberto Restrepo, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
Medicina Intensiva|June 21, 2024
Association of dead space fraction to mortality in patients with COVID-19-related ARDS: A historical cohort observational studyCarlos Carvajal, Nelson Darío Giraldo Ramirez, Andrés David De La Hoz Castro, et al.
Endocrine-Related Cancer|June 1, 2021
Treatment outcomes of advanced digestive well-differentiated grade 3 NETsLouis de Mestier, Angela Lamarca, Jorge Hernando, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Cell Reports|August 4, 2023
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotypeEstefania Cuesta-Borràs, Cándida Salvans, Oriol Arqués, et al.
Translational Oncology|April 9, 2023
Impact of the COVID-19 pandemic in the early-onset colorectal cancerIosune Baraibar, Ariadna García, Francesc Salvà, et al.
Nature Communications|August 8, 2024
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2019
Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine CarcinomasJaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, et al.
Critical Care (London, England)|September 19, 2008
Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trialGisela Del Carmen De La Rosa, Jorge Hernando Donado, Alvaro Humberto Restrepo, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
Medicina Intensiva|June 21, 2024
Association of dead space fraction to mortality in patients with COVID-19-related ARDS: A historical cohort observational studyCarlos Carvajal, Nelson Darío Giraldo Ramirez, Andrés David De La Hoz Castro, et al.
Endocrine-Related Cancer|June 1, 2021
Treatment outcomes of advanced digestive well-differentiated grade 3 NETsLouis de Mestier, Angela Lamarca, Jorge Hernando, et al.
Pageof 10